1.Comprehensive Approach to Prevention of Central Line-Associated Bloodstream Infection.
Pyoeng Gyun CHOE ; Hong Bin KIM
Korean Journal of Nosocomial Infection Control 2013;18(2):33-38
Central lines are indispensable in hospital care. The main complication resulting from their use is central line-associated bloodstream infection (CLABSI). CLABSI is one of the most frequent healthcare-associated infections associated with high costs, morbidity, and potential lethality. Recent studies on CLABSI prevention show that a multifaceted approach to improving central line insertion and maintenance practices results in decreased CLABSI rates. The question today, then, is not 'what to do,' but 'how to do it.'
Catheter-Related Infections
;
Central Venous Catheters
;
Comprehensive Health Care
2.Human immunodeficiency virus infection in the elderly.
Pyoeng Gyun CHOE ; Nam Joong KIM
Korean Journal of Medicine 2010;79(4):356-361
The proportion of human immunodeficiency virus (HIV) infected patients aged 50 and older has greatly increased since the beginning of the epidemic, particularly after the introduction of combination antiretroviral therapy. In Korea, 25% of those infected with HIV were older than 50 in 2009. Older untreated patients with HIV demonstrate faster rates of CD4 lymphocyte loss and more rapid progression to acquired immunodeficiency syndrome and death than younger individuals. Most studies have shown that compared with younger patients, patients over 50 generally have a slower immunologic response to antiretroviral therapy, despite a better virological response. Management of HIV infection in older patients is particularly complex, mainly because they are more likely to have co-morbidities necessitating specific medications that may interact with antiretroviral drugs. Patients living longer with HIV are more likely to develop diseases associated with aging, and at an earlier age, than those without HIV. These include dementia, coronary artery disease, dyslipidemia, metabolic syndrome, diabetes, and osteoporosis.
Acquired Immunodeficiency Syndrome
;
Aged
;
Aging
;
Coronary Artery Disease
;
Dementia
;
Dyslipidemias
;
HIV
;
HIV Infections
;
Humans
;
Korea
;
Lymphocytes
;
Osteoporosis
4.Vaccines and Treatment of Coronavirus Disease 2019
Korean Journal of Medicine 2020;95(6):364-369
In December 2019, a new strain of betacoronavirus, severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Subsequently, the virus quickly spread worldwide and the World Health Organization declared COVID-19 a global pandemic on March 11, 2020. In response to the pandemic, many researchers are working on repurposing existing drugs to alter the course of severe COVID-19, and are testing experimental treatments. Among antiviral agents, remdesivir, an RNA-dependent RNA polymerase inhibitor, showed clinical benefit in a randomized clinical trial. In October 2020, the Food and Drug Administration approved remdesivir for treating hospitalized patients with COVID-19, making it the first drug approved for the disease. The race to produce safe, effective vaccines is also progressing at unprecedented speed, with over 200 under development and 45 candidates already being tested in human clinical trials (as of October 2020).
5.Vaccines and Treatment of Coronavirus Disease 2019
Korean Journal of Medicine 2020;95(6):364-369
In December 2019, a new strain of betacoronavirus, severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Subsequently, the virus quickly spread worldwide and the World Health Organization declared COVID-19 a global pandemic on March 11, 2020. In response to the pandemic, many researchers are working on repurposing existing drugs to alter the course of severe COVID-19, and are testing experimental treatments. Among antiviral agents, remdesivir, an RNA-dependent RNA polymerase inhibitor, showed clinical benefit in a randomized clinical trial. In October 2020, the Food and Drug Administration approved remdesivir for treating hospitalized patients with COVID-19, making it the first drug approved for the disease. The race to produce safe, effective vaccines is also progressing at unprecedented speed, with over 200 under development and 45 candidates already being tested in human clinical trials (as of October 2020).
6.How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea
Do Hyeon PARK ; Chang Kyung KANG ; Pyoeng Gyun CHOE ; Nam Joong KIM ; Wan Beom PARK ; Myoung-don OH
Journal of Korean Medical Science 2022;37(49):e353-
Since 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, and the coronavirus disease 2019 (COVID-19) pandemic currently continues.In response to this unprecedented pandemic, several researchers and medical staff have struggled to find appropriate treatments for COVID-19. Patients with mild symptoms can recuperate with symptomatic care, however establishing treatment for severe to critically ill patients who can have a high mortality has been essential. Accordingly, the guidelines for COVID-19 treatment have evolved through numerous trials and errors and have been relatively well established to date. In the Republic of Korea, several evidence-based guidelines for COVID-19 treatment were released and revised, reflecting various research and regional medical conditions. To date, approximately 3 years after the beginning of the COVID-19 pandemic, we are reflecting on the changes in the guidelines thus far and have summarized the treatment experience of severe to critically ill patients with COVID-19. The Korean guidelines for COVID-19 treatment have been updated continuously as the National Institutes of Health (NIH) guidelines have changed. Dexamethasone is currently used as the backbone for the treatment of severe to critically ill patients with COVID-19, and remdesivir, baricitinib, and tocilizumab can be added depending on a patient’s situation. In addition, venous thromboembolism prophylaxis is one of the important adjunctive therapies for patients with severe COVID-19. In the clinical field, treatment of severely ill patients with COVID-19 based on guidelines is widely practiced by medical staff and established currently.
7.In vitro antiviral activity of ribavirin against severe fever with thrombocytopenia syndrome virus.
Myung Jin LEE ; Kye Hyung KIM ; Jongyoun YI ; Su Jin CHOI ; Pyoeng Gyun CHOE ; Wan Beom PARK ; Nam Joong KIM ; Myoung don OH
The Korean Journal of Internal Medicine 2017;32(4):731-737
BACKGROUND/AIMS: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV), a novel bunyavirus. As yet, there is no effective antiviral therapy for SFTS. Ribavirin is a broad-spectrum antiviral agent, which has been tried for treatment of SFTS. In this study, antiviral activity of ribavirin against SFTSV has been investigated. METHODS: Vero cell-grown SFTSV strain Gangwon/Korea/2012 was treated with ribavirin at various concentrations. Antiviral activity of ribavirin was evaluated by inhibition of the SFTSV cytopathic effect in Vero cells and quantification of viral RNA load in culture supernatant using one-step real-time reverse transcription polymerase chain reaction. Cytotoxicity of ribavirin was determined by a tetrazolium-based colorimetric method. RESULTS: Ribavirin reduced SFTSV titers in a dose-dependent manner, with a half-maximal inhibitory concentration ranged from 3.69 to 8.72 μg/mL. Cytopathic effects were reduced as ribavirin concentration increased. No significant cytotoxicity was detected at ribavirin concentrations of ≤ 31.3 μg/mL. CONCLUSIONS: Ribavirin exhibited inhibitory activity against SFTSV replication in vitro, which suggests that ribavirin can be used as a potential antiviral agent for SFTS.
Antiviral Agents
;
Bunyaviridae Infections
;
Communicable Diseases, Emerging
;
Fever*
;
In Vitro Techniques*
;
Methods
;
Orthobunyavirus
;
Phlebovirus
;
Polymerase Chain Reaction
;
Reverse Transcription
;
Ribavirin*
;
RNA, Viral
;
Thrombocytopenia*
;
Vero Cells
8.A Case of Varicelliform Zoster in a Patient Treated with Etanercept for Ankylosing Spondylitis.
Sun Hee NA ; Eun Young NAM ; Pyoeng Gyun CHOE ; Wan Beom PARK ; Nam Joong KIM ; Myoung Don OH ; Eun Young LEE ; Nak Hyun KIM
Journal of Rheumatic Diseases 2015;22(3):186-189
Tumor necrosis factor-alpha (TNF-alpha) inhibitors are increasingly used in treatment of inflammatory disorders because of their immunomodulatory efficacy. Increased risk of infection is an adverse effect of anti-TNF-alpha therapy. The incidence rate and severity of herpes zoster is significantly higher in patients on anti-TNF-alpha therapy than in the general population. The clinical presentation of varicella zoster virus infection is also often atypical in these patients. We experienced a patient who presented with a disseminated varicelliform rash while on etanercept therapy for ankylosing spondylitis.
Exanthema
;
Herpes Zoster*
;
Herpesvirus 3, Human
;
Humans
;
Incidence
;
Spondylitis, Ankylosing*
;
Tumor Necrosis Factor-alpha
;
Etanercept
9.Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency.
Pyoeng Gyun CHOE ; Wan Beom PARK ; Jin Su SONG ; Nak Hyun KIM ; Kyoung Ho SONG ; Sang Won PARK ; Hong Bin KIM ; Nam Joong KIM ; Myoung Don OH
Journal of Korean Medical Science 2010;25(10):1427-1430
Hyperbilirubinemia is frequently observed in Caucasian HIV patients treated with atazanavir. UDP-glucuronosyltransferase 1A1 polymorphism, UGT1A1*28, which is associated with atazanavir-induced hyperbilirubinemia, is less common in Asians than in Caucasians. However, little is known about the incidence of atazanavir-associated hyperbilirubinemia in Asian populations. Our objective was to investigate the incidence of and tolerability of atazanavir-associated hyperbilirubinemia in Korean HIV patients. The prevalence and cumulative incidence of atazanavir-associated hyperbilirubinemia and UGT1A1*28 allele frequency was investigated in 190 Korean HIV-infected patients treated with atazanavir 400 mg per day. The UGT1A1*28 were examined by direct sequencing of DNA from peripheral whole blood. The UGT1A1*28 allele frequency was 11%. The cumulative incidence of any grade of hyperbilirubinemia was 77%, 89%, 98%, and 100%, at 3, 12, 24, and 30 months, respectively. The cumulative incidence of severe (grade 3-4) hyperbilirubinemia was 21%, 41%, 66%, and 75%, at 3, 12, 24, and 30 months, respectively. However, the point prevalence of severe hyperbilirubinemia did not increase with time and remained around 25%. Our data suggest that atazanavir-associated hyperbilirubinemia is common but transient in a population with low UGT1A1*28 allele frequency.
Adult
;
Alleles
;
Anti-HIV Agents/*adverse effects/therapeutic use
;
Asian Continental Ancestry Group/*genetics
;
Female
;
Follow-Up Studies
;
Gene Frequency
;
Glucuronosyltransferase/blood/*genetics
;
HIV Infections/complications/*drug therapy
;
Humans
;
Hyperbilirubinemia/complications/*epidemiology/genetics
;
Incidence
;
Male
;
Middle Aged
;
Oligopeptides/*adverse effects/therapeutic use
;
Promoter Regions, Genetic
;
Pyridines/*adverse effects/therapeutic use
;
Republic of Korea
10.The limited role of serum galactomannan assay in screening for invasive pulmonary aspergillosis in allogeneic stem cell transplantation recipients on micafungin prophylaxis: a retrospective study.
Ryul KIM ; Youngil KOH ; Dong Yeop SHIN ; Pyoeng Gyun CHOE ; Nam Joong KIM ; Sung soo YOON ; Myoung don OH ; Wan Beom PARK ; Inho KIM
Blood Research 2017;52(4):300-306
BACKGROUND: We evaluated the outcomes of serum galactomannan (GM) assay for the screening of invasive pulmonary aspergillosis (IPA) in allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients while on primary antifungal prophylaxis (PAP). METHODS: This study included patients with hematologic disorders who underwent alloHSCT from January 2013 to November 2015. Patients received routine PAP with fluconazole before 2014 and micafungin after 2014; serum GM tests were performed and retrospectively analyzed. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of serum GM tests for detection of probable/proven IPA were evaluated. The serial change of serum GM levels was illustrated on a time series plot. RESULTS: A total of 136 alloHSCT recipients at Seoul National University Hospital were included in the study. Fluconazole was administered in 72 patients for PAP, while micafungin was administered in the remaining 64 patients. The overall sensitivity, specificity, and NPV of serum GM assays were 95.8% (95% confidence interval [CI] 78.9–99.9%), 93.8% (95% CI 91.7–95.5%), and 99.8% (95% CI 99.1–100.0%), respectively. However, the PPV of GM tests was relatively low at 35.4% (95% CI 23.9–48.2%). The serial change in serum GM levels differed according to the antifungal agents used. With effective PAP using micafungin, serial serum GM levels showed zero order kinetics during the neutropenic period. CONCLUSION: Although the serum GM assay is a sensitive and specific test for detecting IPA in alloHSCT recipients, its role for routine surveillance in an era of effective PAP with micafungin is limited.
Antifungal Agents
;
Fluconazole
;
Hematology
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Invasive Pulmonary Aspergillosis*
;
Kinetics
;
Mass Screening*
;
Retrospective Studies*
;
Sensitivity and Specificity
;
Seoul
;
Stem Cell Transplantation*
;
Stem Cells*